Certara, Inc. (NASDAQ:CERT) Sees Large Growth in Short Interest

Certara, Inc. (NASDAQ:CERT) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 5,030,000 shares, an increase of 14.3% from the June 15th total of 4,400,000 shares. Approximately 4.6% of the shares of the stock are short sold. Based on an average trading volume of 570,100 shares, the short-interest ratio is presently 8.8 days.

Certara Trading Up 0.3 %

CERT traded up $0.05 on Wednesday, hitting $16.55. The company had a trading volume of 420,163 shares, compared to its average volume of 561,246. The company’s fifty day moving average price is $15.43 and its 200 day moving average price is $16.63. Certara has a 1 year low of $11.81 and a 1 year high of $19.87. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. The firm has a market cap of $2.66 billion, a P/E ratio of -42.43, a PEG ratio of 5.39 and a beta of 1.52.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The company had revenue of $96.65 million for the quarter, compared to analyst estimates of $94.48 million. As a group, equities analysts expect that Certara will post 0.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. KeyCorp cut their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, Barclays lowered their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.44.

Institutional Investors Weigh In On Certara

Institutional investors have recently modified their holdings of the company. Pineridge Advisors LLC acquired a new position in Certara in the 4th quarter valued at about $28,000. Global Retirement Partners LLC boosted its stake in shares of Certara by 5,306.3% in the first quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after purchasing an additional 1,698 shares during the period. YHB Investment Advisors Inc. acquired a new position in shares of Certara in the first quarter valued at approximately $47,000. Pacer Advisors Inc. increased its stake in Certara by 1,704.0% during the 4th quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock worth $224,000 after buying an additional 12,047 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Certara during the 2nd quarter worth approximately $226,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.